The Feinstein Institutes for Medical Research
Manhasset, New York, 11030, United States
Location status: Recruiting
Location contact
Erica Christen, MS
CONTACT
Michelle Gong, AS
CONTACT
NCT Number: NCT06336382
Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.
Interested in participating?
Request Info65 year–85 year
All sexes
Observational
Manhasset, New York, 11030, United States
Location status: Recruiting
Erica Christen, MS
CONTACT
Michelle Gong, AS
CONTACT
Psychotic symptoms that occur in advanced age in the absence of an acute medical condition or prominent mood symptoms can represent the late appearance of primary psychotic disorders such as very late-onset schizophrenia-like psychosis (VLOSP) or delusional disorder, or can presage the appearance of a neurodegenerative condition such as Alzheimer's disease (AD). An episode of non-affective psychosis late in life more than doubles the risk of subsequent neurodegenerative disease, with an average time from psychosis to AD diagnosis of 18 months. The biologic mechanisms responsible for the increased risk of dementia in those who experience psychosis are unclear. One hypothesis is reverse causality, in which inchoate neurodegeneration is responsible for psychotic symptoms that emerge in the absence of traditional cognitive hallmarks of dementia. The psychosis then heralds the inception of illness that will eventuate in cognitive decline. The investigators will utilize neurodegenerative biomarkers in the form of novel PET imaging tracers, plasma immunoassays and non-invasive neurophysiologic measurements to test this hypothesis in a pilot cohort of elderly subjects suffering with psychosis occurring in late-life without dementia for comparison with a cohort of healthy elderly controls (HEC)s who are participating in a study focused on those with dementia.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will be scanned with novel tau PET tracer [18F] PI-2620 to determine whether neurofibrillary tangle pathology is present.
Other names: Tau PET scan
Time frame: Each subject will have one PET imaging scan at visit 3 (week 4).
To determine whether there are increases in tau pathology in those with psychotic episodes that occur late in life employing tau PET ligands, and whether those increases are etiologic contributors to a stable psychosis or are a presage of an incipient cognitive decline.
Time frame: Each subject will have blood collected at visit 1 or 2 (week 1 or 2).
Plasma samples will be collected via venipuncture from LOP subjects and batch shipped to Quanterix Inc. for ptau analyses and quantification on the SiMOA SR-X analyzer platform.
Time frame: Each subject will participate in this assessment at visit 2 (week 2).
Prepulse Inhibition of Acoustic Startle (PPI) sessions will be assessed using eyeblink response (electromyography of the orbicularis oculi muscle) to a 115-dB startle stimulus.
Contact information is provided by the study sponsor or research team.
Erica Christen, MS
CONTACT
Nichole Hoehn, MS
CONTACT
Jeremy Koppel
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07645443
Behavior, Brief Psychotic Disorder
Mannheim, Baden-Wurttemberg, Germany
View Trial DetailsNCT06740383
Bipolar 1 Disorder, Bipolar Disorder
Hartford, Connecticut, United States
View Trial DetailsNCT06005766
Delusional Disorder, Mental Disorders
Vaasa, Finland
View Trial DetailsNCT06007105
Acute and Transient Psychotic Disorder, Bipolar Type I Disorder With Psychotic Symptoms
Blantyre, Southern Region, Malawi
View Trial Details